title: Effect of an excess intake of casein hydrolysate containing Val-Pro-Pro and Ile-Pro-Pro in subjects with normal blood pressure, high-normal blood pressure, or mild hypertension.
abstract: A double-blind, placebo-controlled, randomized clinical trial was conducted to evaluate the effects of ingesting an excess of tablets containing casein hydrolysate, incorporating angiotensin I-converting enzyme (ACE) inhibitory peptides such as Val-Pro-Pro (VPP) and Ile-Pro-Pro (IPP), in subjects with blood pressure ranging from normal to mild hypertension. A total of 48 subjects were given either 5 times more than the effective amount of casein hydrolysate or a placebo in tablet form for 4 weeks. In the active group, systolic blood pressure (SBP) decreased significantly as compared with the placebo group. In stratified analysis, however, this antihypertensive effect was not found in normotensive subjects. In addition, neither an acute or nor an excessive reduction in blood pressure nor clinically important adverse events were observed in this study. These findings suggest that intake of a 5-fold excess of tablets containing casein hydrolysate can lead to a mild improvement in hypertension without side effects.
authors.affiliation: R&D Center, Calpis Co., Ltd., Sagamihara, Kanagawa, Japan. yu.ishida@calpis.co.jp
authors.forename: Yu
authors.initials: Y
authors.lastname: Ishida
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Shibata
authors.forename: Ikuo
authors.initials: I
authors.lastname: Fukuhara
authors.forename: Yuki
authors.initials: Y
authors.lastname: Yano
authors.forename: Isao
authors.initials: I
authors.lastname: Takehara
authors.forename: Kyouko
authors.initials: K
authors.lastname: Kaneko
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D015992:Body Mass Index; D001835:Body Weight; D002364:Caseins / Q000008:administration & dosage / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D007564:Japan; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000008:administration & dosage / Q000627:therapeutic use*; D007703:Peptidyl-Dipeptidase A / Q000378:metabolism; D010919:Placebos / Q000008:administration & dosage; D013607:Tablets / Q000008:administration & dosage
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002364:Caseins; D009842:Oligopeptides; D010919:Placebos; D013607:Tablets; C489032:isoleucyl-prolyl-proline; C489031:valyl-prolyl-proline; C475729:casein hydrolysate; D007703:Peptidyl-Dipeptidase A